Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Ansell SM, et al. Among authors: bartlett nl. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13. N Engl J Med. 2022. PMID: 35830649 Clinical Trial.
New therapies in Hodgkin's lymphoma.
Bartlett N. Bartlett N. Clin Adv Hematol Oncol. 2004 Feb;2(2):80, 83. Clin Adv Hematol Oncol. 2004. PMID: 16163165 No abstract available.
Management of advanced stage Hodgkin's lymphoma.
Bartlett NL, Smukler AJ. Bartlett NL, et al. Cancer Treat Res. 2006;131:333-52. doi: 10.1007/978-0-387-29346-2_11. Cancer Treat Res. 2006. PMID: 16704175 Review. No abstract available.
Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV, Bartlett NL. Foyil KV, et al. Among authors: bartlett nl. Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Curr Hematol Malig Rep. 2010. PMID: 20446121 Review.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. Among authors: bartlett nl. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Free article. Clinical Trial.
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD; Cancer and Leukemia Group B. Straus DJ, et al. Among authors: bartlett nl. Blood. 2011 May 19;117(20):5314-20. doi: 10.1182/blood-2010-10-314260. Epub 2011 Feb 25. Blood. 2011. PMID: 21355087 Free PMC article. Clinical Trial.
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, Dipersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA. Smeltzer JP, et al. Among authors: bartlett nl. Biol Blood Marrow Transplant. 2011 Nov;17(11):1646-52. doi: 10.1016/j.bbmt.2011.04.011. Epub 2011 May 3. Biol Blood Marrow Transplant. 2011. PMID: 21601641 Free PMC article.
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD; Cancer Leukemia Group B. Kostakoglu L, et al. Among authors: bartlett nl. Leuk Lymphoma. 2012 Nov;53(11):2143-50. doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28. Leuk Lymphoma. 2012. PMID: 22421007 Free PMC article. Clinical Trial.
280 results